{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"MTD: maximum dose at which \\<one third participants had DLT in Cycle 1. DLT: Grade 3/4 drug-related non hematological toxicity (except Grade 3 nausea, vomiting of \\<3 days, Grade 3 liver enzyme elevation with alanine transaminase/aspartate transaminase and gamma glutamyl transferase that returned to Grade \\<=1 or baseline prior to next dose; Grade 3 fever, infection, hypophosphatemia, hypokalemia, hypocalcemia/hypomagnesemia responsive to oral supplementation). Non-hematological toxicity causing \\>=14 days delay between treatment cycles. Haematological DLTs included: Grade 4 neutropenia/platelets\\<75,000/mm\\^3 on Day 8 that does not resolve to absolute neutrophil count \\>=750/mm\\^3 and platelets\\>=75,000/mm\\^3 by Day 11, neutropenia for \\>7 days; platelet count \\<25,000/mm\\^3, or required platelet transfusion, on 2 separate days within 7-day period;Grade 3 thrombocytopenia complicated by bleeding and/or required platelet transfusion;myelosuppression causing \\>14 days delay between treatment cycles.","groups":[{"description":"All participants received eribulin mesylate 1.1 mg/m\\^2 or 1.4 mg/m\\^2 or 1.8 mg/m\\^2 or 1.4 mg/m\\^2 in PK expansion, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to a maximum of 8 cycles or until PD or unacceptable toxicity or drug related DLT's.","id":"OG000","title":"Part A1: All Participants"}],"paramType":"NUMBER","populationDescription":"The dose evaluable set (DES) included all participants who were judged as DLT evaluable as recorded in the database. In order to be DLT evaluable, all participants had to complete Cycle 1.","reportingStatus":"POSTED","timeFrame":"First dose of study drug (Baseline) up to Cycle 1 Day 21","title":"Maximum Tolerated Dose (MTD) of Eribulin Mesylate","type":"PRIMARY","unitOfMeasure":"mg/m^2"}